BNIP3L Is a New Autophagy Related Prognostic Biomarker for Melanoma Patients Treated With AGI-101H.
Apoptosis Regulatory Proteins
/ metabolism
Autophagy
/ physiology
Biomarkers, Tumor
/ metabolism
Cancer Vaccines
/ immunology
Female
Humans
Male
Melanoma
/ immunology
Membrane Proteins
/ metabolism
Middle Aged
Prognosis
Proto-Oncogene Proteins
/ metabolism
Retrospective Studies
Skin Neoplasms
/ immunology
Tumor Suppressor Proteins
/ metabolism
Melanoma, Cutaneous Malignant
BNIP3L
Melanoma
autophagy
biomarker
melanoma vaccine
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
10
05
2020
revised:
29
05
2020
accepted:
31
05
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
14
7
2020
Statut:
ppublish
Résumé
Skin melanoma belongs to the most invasive malignancies with no cure for a progressing disease. Personalized therapy would allow for the selection of patients that will benefit from treatment. For this purpose, proper predictive biomarkers must be defined. Allogeneic whole-cell gene-modified therapeutic melanoma vaccine (AGI-101H) was applied in advanced melanoma patients. Humoral responses were analyzed using SEREX, and in silico gene expression analysis in TCGA melanoma patients was performed. A specific antibody response was raised against an antigen identified as BNIP3L, which correlated with a good prognosis. Moreover, AGI-101H directs an immune response against autophagy, as BNIP3L is a marker of this process. Medium and high expression of BNIP3L was also linked with longer overall survival. BNIP3L is a candidate prognostic marker of clinical outcome of melanoma patients treated with AGI-101H, and may be considered as a prediction marker for patient survival.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Skin melanoma belongs to the most invasive malignancies with no cure for a progressing disease. Personalized therapy would allow for the selection of patients that will benefit from treatment. For this purpose, proper predictive biomarkers must be defined.
MATERIALS AND METHODS
METHODS
Allogeneic whole-cell gene-modified therapeutic melanoma vaccine (AGI-101H) was applied in advanced melanoma patients. Humoral responses were analyzed using SEREX, and in silico gene expression analysis in TCGA melanoma patients was performed.
RESULTS
RESULTS
A specific antibody response was raised against an antigen identified as BNIP3L, which correlated with a good prognosis. Moreover, AGI-101H directs an immune response against autophagy, as BNIP3L is a marker of this process. Medium and high expression of BNIP3L was also linked with longer overall survival.
CONCLUSION
CONCLUSIONS
BNIP3L is a candidate prognostic marker of clinical outcome of melanoma patients treated with AGI-101H, and may be considered as a prediction marker for patient survival.
Identifiants
pubmed: 32620611
pii: 40/7/3723
doi: 10.21873/anticanres.14361
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
BNIP3L protein, human
0
Biomarkers, Tumor
0
Cancer Vaccines
0
Membrane Proteins
0
Proto-Oncogene Proteins
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3723-3732Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.